<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820767</url>
  </required_header>
  <id_info>
    <org_study_id>SENPARIC-2011-01</org_study_id>
    <nct_id>NCT01820767</nct_id>
    <nct_alias>NCT02210533</nct_alias>
  </id_info>
  <brief_title>Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients</brief_title>
  <acronym>SENPARIC</acronym>
  <official_title>Paricalcitol Action on Parameters of Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease Stage Vd Carriers Tunneled Hemodialysis Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ricardo Mouzo Mirco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital El Bierzo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of
      inflammatory and oxidative stress parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter
      due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This
      study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus atorvastatin
      treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients wiht CKD stage Vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment wiht visits and analysis</time_frame>
    <description>Measure parameter: IL-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Measure unit: IL-4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>IL-5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>IL-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>IL-13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>TNF-beta</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD56</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD69</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>CD95</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>iNOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>PGE2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>FGF-23</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin requirements variations</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Fe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess potential benefits inflammatory markers</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>PTHi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Body Mass Index (BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Abdominal circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Triceps skin fold circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Parameters</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaemia parameters</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Hemogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaemia Parameters</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin requirement variations</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin requirement variations</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Transferrin saturation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin requirements variations</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>B12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin requirements variations</measure>
    <time_frame>12 weeks of treatment with visits and analysis</time_frame>
    <description>Folic Acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess potential benefits in inflammatory markers</measure>
    <time_frame>16 weeks, the complete duration of the study</time_frame>
    <description>Kt</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol, Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol, atorvastatin</intervention_name>
    <description>Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.
Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.</description>
    <arm_group_label>Paricalcitol, Atorvastatin</arm_group_label>
    <other_name>G2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin: 20 mg/day oral (1 take) during 12 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>G3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vd CKD patients using haemodialysis during 3 or more months.

          -  Tunnelized-bearer permanent catheters on haemodialysis at last 6 months previous at
             the beginning of the study. .

          -  Kt stable, over 45 litres on both sexs.

          -  Patients in treatment wiht atorvastatin

          -  Patients without infectious or inflammatory processes over 8 weeks.

          -  Two consecutive PTH &lt; than 400 pg/ml; Ca&lt;10.2 and P &lt;7.0 mg/dl.

        Exclusion Criteria:

          -  Patients &gt; 18 years.

          -  Pregnant women.

          -  Patients hospitalized 4 weeks before the beginning of the treatment.

          -  Immunosuppressor intake.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Mouzo Mirco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital El Bierzo, Fuentesnuevas Ponferrada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital El Bierzo. Servicio de Nefrología.</name>
      <address>
        <city>Ponferrada</city>
        <state>(León).</state>
        <zip>24411,</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital El Bierzo</investigator_affiliation>
    <investigator_full_name>Ricardo Mouzo Mirco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Vd-stadium.</keyword>
  <keyword>Inflammatory patterns</keyword>
  <keyword>Paricalcitol</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

